ELSEVIER Critical Reviews in Oncology/Hematology 26 (1997) 117- 135 criticll ReviWJ in oncology Hematology Epstein- Barr virus oncogenesis Hans Knecht ‘,*, Christoph Berger ‘, A. Samer Al-Homsi ‘, Catherine McQuain ‘, Pierre Brousset b A LINK Laboratories at the Cancer Center, University of Massachusetts Medical Center, Division of Hematology/Oncology, 55 Luke Avenue North, Worcester, MA, USA b Laboratoire d’Anafomie Pathologique, CH U Purpan, Toulouse, France Accepted 15 June 1997 Contents 1. Introduction. 2. Transforming proteins 118 2.1. LMPl 118 2.1.1. Molecular and functional characterization. 118 2.1.1 .l. Molecular structure 11X 2.1.1.2. Oncogenic properties 120 2.1.1.3. Immunomodulating properties 120 2.1.1.4. NF-KB mediated transcription 120 2.1.1.5. TRAF-interaction 121 2.1.1.6. Supressor functions 122 2.1.1.7. Promoter regulation 122 2.1.2. Clinical data 122 2.2. EBNAl 124 2.2.1. Molecular and functional characterization 124 2.2.1.1. Structure and function. 124 2.2.1.2. Promoter regulation 125 2.2.1.3. Escape from immunosurveillance. 125 2.2.1.4. Oncogenic properties 125 2.2.2. Clinical data 125 2.3. EBNAZ 126 2.3.1. Molecular and functional characterization. 126 2.3.1.1, Transcriptional activation 126 2.3.1.2. Interacting transcription factors 127 2.3.2. Clinical data 121 3. Future directions in translational research. Acknowledgement Reviewers References Biographies. 118 12X 12X 128 128 135 * Corresponding author. Tel.: + 1 508 X563702; Fax: + 1 508 8566715. 1040-842X/97/$32.00 6 1997 Elsevier Science Ireland Ltd. All rights reserved PII SlO40-842X(97)00016-4